Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Table 4 Response of HBeAg-negative patients to various doses and duration of PEG-IFN alfa-2a therapy analyzed according to endpoint

Dose/duration and endpoint	EOT	Time after end of treatment (years)
Dose/duration and endpoint	EOT	0.5	1	2	3	4	5
90 μg/48 week
ALT normalization	1/3	1/3	1/3	1/3	1/3	1/3	1/2
Low HBV (<4.3 log copies/mL)	2/3	1/3	0/3	1/3	1/3	1/3	1/2
180 μg/48 week
ALT normalization	1/2	2/2	2/2	0/2	0/2	0/2	0/2
Low HBV (<4.3 log copies/mL)	2/2	0/2	0/2	0/2	0/2	0/2	0/2

ISSN: 1743-422X